Press Releases

Press Releases

Octagos Health announces strategic investments in product, AI and talent

Following its recent $43 million Series B funding, the company is expanding its data integration capabilities to include a broader range of devices, including wearables, heart failure monitoring, and remote patient monitoring.

Elutia announces first patient implant of EluPro, the world’s first drug-eluting bioenvelope for cardiac pacemakers and neurostimulators

The procedure was performed in Greenville, North Carolina.

2023 Hearst Health Prize - AI for Incidental CAC

Congratulations to Stanford Medicine on winning the 2023 Hearst Health Prize for its artificial intelligence solution that helps identify patients at risk for heart attack by scoring incidental coronary artery calcium (CAC) on non-gated chest CTs.

DASI Simulations' PrecisionTAVI gets CMS Hospital Outpatient Billing Code

Predictive model generation for pre-planning a cardiac procedure now reimbursable by Medicare at approximately $1,000 per model

 

Echo IQ's breakthrough research on cardiovascular health continues with unveiling of AI-driven aortic stenosis and mitral regurgitation detection results at ESC 2023 Congress

Late-Breaking Science sessions reveal revolutionary findings on severe aortic stenosis and mild-to-severe mitral regurgitation identification through innovative AI technology.

 

Keystone Perfusion Services, PC recognized for life-saving contribution during COVID-19 pandemic, secures fifth consecutive year on Inc. 5000 list
| Submitted by: Keystone Perfusion Services, PC

The company's multifaceted healthcare staffing solutions play a pivotal role in transforming patient care and elevating industry standards.

 

Corazon and the Society for Cardiovascular Angiography and Interventions announce partnership

The agreement formally endorses Corazon’s cardiovascular accreditation.

Arineta announces SpotLight Duo, the world’s first dedicated cardiovascular and thoracic CT system

Arineta Cardio Imaging is excited to announce the FDA 510(k) clearance of the SpotLight and SpotLight Duo family of cardiovascular CT scanners.

Study Confirms Ultromics’ AI Can Improve HFpEF Detection Using a Single Echocardiogram View

 

Researchers and engineers at Mayo Clinic and Ultromics developed technology that can detect HFpEF using a single A4C echocardiogram clip, to help clinicians detect a complex form of heart failure easily and accurately. 

 

Cassling connects cardiologists with revolutionary AI software

The Midwest company will begin offering EchoSolv, an artificial intelligence clinical decision support platform designed to help detect severe aortic stenosis, to providers throughout the country.

 

DASI Simulation’s Precision TAVI earns FDA clearance
| Submitted by: DASI Simulations

Precision TAVI is the first FDA-approved predictive modeling tool for medical teams planning TAVR procedures.

 

 

RecoverRite®, American College of Cardiology Collaborate to Change the Face of Cardiovascular Patient Education

RecoverRite’s Online Heart Learning Center to feature ACC’s CardioSmart patient tools and resources.

Study shows PulseAI’s deep learning algorithm outperforms the Apple Watch ECG algorithm in detecting atrial fibrillation

PulseAI, a leader in the development of cutting-edge AI-powered ECG software, has released the results of a clinical study that has shown the superiority of its deep learning AI over the Apple Watch ECG algorithm in the detection of atrial fibrillation.

 

$20M gift announced by the Rooney Foundation in support of enhanced cardiac care at NCH

NAPLES, Fla. – February 20, 2023   The NCH Healthcare System is proud to announce a $20 million naming gift from the Rooney Foundation, which is the philanthropic arm of the former U.S. Representative for Florida's 19th congressional district and his wife, Francis and Kathleen Rooney.  In recognition of increasing their $8 million pledge announced last July, the entire cardiac program across NCH Healthcare System will be renamed “The Rooney Heart Institute.”

NCH announces second historic gift in as many weeks totaling a record $40M in support of enhanced care

NAPLES, Fla. – February 21, 2023   On the heels of our historic $20 Million gift announcement made last week, NCH is proud to announce yet a second $20 million naming gift in as many weeks from Diana and Don Wingard.  This generous gift will provide the necessary funds to ensure that the NCH Stroke program continues to provide the highest level of care and treatment to patients in Southwest Florida.  Additionally, in recognition of the extraordinary pledge, the entire stroke program across NCH will be renamed the “Wingard Stroke Institute.”

Patient Image Exchange puts patients 'in the driver’s seat'

When using this service, patients have the ability to upload and share data without limitations. From radiology CDs to PDFs or JPG files, patients can use their smartphone connected to the Patient Image Exchange app and upload images, share lab results, immunizations records, nurses’ notes, dental images and much more.

 

Ancora Heart appoints David J. Tucker as chief financial officer

Ancora Heart has hired senior financial leader David J. Tucker as its chief financial officer. This is the company's second C-suite hire in 2022, following the addition of Mark Miles as chief commercial officer in June.

Geneticure presents data successfully identifying responders and non-responders to renal denervation using genetic screening

Geneticure, a global leader in the genetic variability of response to hypertension treatments, presented data at the 2022 American Heart Association Scientific Sessions meeting from a recent clinical study in which they were able to successfully predict patients who will respond to renal denervation (RDN). In addition, the Geneticure test for renal denervation also identified patients with an increase in blood pressure, following the procedure.

Cardiac Insight Comments on CMS Announcement of National Payment Rates for Long-Term Continuous ECG (LT-ECG) Monitoring in 2023

Long-awaited milestone gives physicians and their patients greater access to prescription cardiac arrhythmia detection solutions, including the company’s Cardea SOLO™ ECG System

Medtronic Launches IDE Study to Evaluate the Abre(TM) Venous Self-Expanding Stent System in Patients with Deep Venous Disease

DUBLIN — January 26, 2018 — Medtronic plc (NYSE: MDT) today announced the initiation of its investigational device exemption (IDE) study for the Abre(TM) venous self-expanding stent system. The ABRE IDE Study will evaluate the safety and effectiveness of the Abre stent in subjects with iliofemoral venous outflow obstruction.

Medtronic Launches ENCHANT Study to Evaluate ChEVAR Parallel Graft Technique with the Endurant(TM) II/IIs Stent Graft System

DUBLIN — January 24, 2018 — Medtronic plc (NYSE: MDT) today announced the launch of the ENCHANT (ENdurantCHEVAR New Indication Trial) study. The post-market, non-interventional, multi-center, non-randomized, single-arm study will enroll approximately 150 patients across 25 sites in Europe and Russia, and will evaluate the safety and performance of a ChEVAR procedure using the Endurant(TM) II/IIs stent graft system in a real-world setting.

Noted Cardiologists Jennifer H. Mieres, MD and Stacey E. Rosen, MD Launch Call to Action and New Book "Heart Smart For Women: Six S.T.E.P.S. in Six Weeks To Heart-Healthy Living"

NEW YORK, Jan. 22, 2018 — Noted cardiologists, Jennifer H. Mieres, MD, and Stacey E. Rosen, MD, launch Heart Smart For Women; Six S.T.E.P.S. in Six Weeks To Heart- Healthy Living; a new book that demystifies the science, biology and statistics surrounding heart disease while providing a user-friendly program for successful heart-healthy living.

Baxter Announces U.S. FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin

Baxter International Inc. (NYSE: BAX), a global leader in sterile medication production and delivery, today announced the U.S. Food and Drug Administration (FDA) approval of Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin). Bivalirudin is a specific and direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).

FDA Mini-Sentinel Assessment Confirms Safety and Effectiveness of XARELTO® (rivaroxaban) and its Association with a Lower Risk of Ischemic Stroke vs. Warfarin

TITUSVILLE, N.J., Jan. 16, 2018 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced findings from the U.S. Food and Drug Administration's (FDA) Mini-Sentinel assessment, confirming the positive safety and efficacy profile of XARELTO® (rivaroxaban) established in the phase III ROCKET AF clinical trials, were published in Pharmacoepidemiology & Drug Safety.

International Biophysics obtains FDA 510k clearance for the FloPump® 32 centrifugal heart pump

International Biophysics Corporation, a global medical device manufacturer based in Austin, Texas, announced they have received FDA 510k clearance for their FloPump 32 centrifugal disposable heart pump.

Medtronic Receives FDA Clearance for Riptide(TM) Aspiration System

DUBLIN — January 16, 2018 — Medtronic plc (NYSE:MDT) today announced that the company's Neurovascular business unit received U.S. Food and Drug Administration (FDA) clearance of the Riptide(TM) Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio.

Dr. Kirk N. Garratt Named Medical Director of Christiana Care’s Center for Heart & Vascular Health

Kirk N. Garratt, M.Sc, M.D, has been appointed medical director of Christiana Care Health System’s Center for Heart & Vascular Health. Dr. Garratt succeeds Tim Gardner, M.D., who retired after 12 years of dedication to Christiana Care and the Delaware community.

New Study Shows Superiority of Intrathecal Baclofen Therapy (ITB Therapy(SM)) Over Oral Medication for the Treatment of Severe Post-Stroke Spasticity

DUBLIN — January 11, 2018 — Medtronic plc (NYSE:MDT) today announced the publication of results from the 'Spasticity In Stroke-Randomised Study' (SISTERS) trial in the Journal of Neurology, Neurosurgery & Psychiatry (JNNP). These results demonstrate the superiority of Medtronic ITB TherapySM with Lioresal®Intrathecal (baclofen injection) delivered via the SynchroMed(TM) II Infusion System compared to conventional medical management (CMM) for the reduction of severe post-stroke spasticity (PSS) in adults.

Cordis and Medinol Announce First U.S. Commercial Implants of Innovative EluNIR™ Drug-Eluting Stent

DUBLIN, Ohio, January 11, 2018 — Cordis, a Cardinal Health company, and Medinol today announced that the first commercial cases using the EluNIR™ drug-eluting stent (DES) in the United States were performed at New York-Presbyterian Hospital/Columbia University Medical Center in New York City and the Piedmont Heart Institute in Atlanta.

First Patient Enrolled in Investigational Study of the GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System

FLAGSTAFF, Ariz. (JANUARY 3, 2018) — W. L. Gore & Associates, Inc. (Gore) today announced the first implant of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the United States.

Positive Five-Year Data Published for MiStent in EuroIntervention

DURHAM, N.C., Jan. 9, 2018 — Micell Technologies, Inc. announced the recent online publication of five-year data from the DESSOLVE I and II trials.

Excel Medical’s WAVE Clinical Platform Receives FDA Clearance

Jupiter, Fla. — January 8, 2018 — Excel Medical launches the first FDA-cleared patient surveillance system. The WAVE Clinical Platform is the first of its kind cleared for marketing.

New FDA MR-Conditional Labeling Approvals Further Expand Abbott's Portfolio of MRI-Ready Devices

Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for the Quadra Assura MPTM Cardiac Resynchronization Therapy Defibrillator (CRT-D) and Fortify AssuraTM Implantable Cardioverter Defibrillator (ICD), two of the company's most widely-used high voltage medical devices.

Bob White Named Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group; Chris Lee to Assume Leadership of Medtronic's Asia Pacific Region

Medtronic plc (NYSE: MDT) announced today that Bob White, previously Senior Vice President and President of Medtronic's Asia Pacific (APAC) Region, has been named Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group (MITG). In addition, the company announced that Chris Lee, Senior Vice President and President of Medtronic's Greater China Region, will assume the position of APAC Region President.

FDA grants fast track designation to Renova Therapeutics’ RT-100 AC6 gene transfer for the treatment of heart failure

San Diego, Calif. — Renova™ Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s lead product candidate, RT-100 AC6 gene transfer (Ad5.hAC6), for the treatment of heart failure with reduced ejection fraction (HFrEF).

New Dashboard Application from Siemens Healthineers Provides Insights into Cardiology Operations

Malvern, Pa., December 11, 2017 — Siemens Healthineers has launched teamplay Cardio, a new cardiology dashboard application within the Siemens Healthineers Digital Ecosystem. Part of teamplay—the company’s cloud-based network that enables access to metrics from a facility’s imaging fleet—this new application helps cardiology departments better understand their performance and status.

Eating Yogurt May Help Reduce Chronic Inflammation in Women, New Clinical Trial Reveals

ROSEMONT, Ill., Dec. 11, 2017 — Eating yogurt on a regular basis may help reduce measures of chronic inflammation in women and support a healthy digestive system, researchers from University of Wisconsin-Madison College of Agricultural and Life Sciences (UW-Madison) report in the British Journal of Nutrition.

Novo Nordisk Receives FDA Approval of OZEMPIC® (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes

PLAINSBORO, N.J., Dec. 5, 2017 — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for OZEMPIC® (semaglutide) injection 0.5 mg or 1 mg, a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Corindus Partners with Houston Methodist DeBakey Heart & Vascular Center to Launch Premier Robotic Training Site for Physicians

Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that Houston Methodist DeBakey Heart & Vascular Center has launched the first vascular robotic program in the Houston area with the installation of two CorPath® GRX Systems. In addition and as part of the program launch, Corindus will partner with Houston Methodist to develop a Global Center of Excellence that will seek to advance clinical research on robotics and to train interventional cardiologists on robotic-assisted percutaneous coronary interventions (PCI).

BioTelemetry, Inc. Enters Agreement to Provide Cardiac Monitoring for Apple’s Heart Study

BioTelemetry, Inc., the leading mobile and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today a partnership with Apple to provide cardiac monitoring services in conjunction with the Apple Heart Study.